Asymchem Group released its 2026 H1 Report detailing steady revenue growth and progress across client segments.

Asymchem (Stock Code: 002821.SZ / 6821.HK) is a leading global CDMO established in 1995 in North Carolina, U.S., dedicated to delivering integrated, end-to-end solutions across the pharmaceutical value chain. Operating from a global network of R&D and manufacturing facilities in China, the U.S and UK, Asymchem employs more than 9,000 professionals worldwide, with 45% of those dedicated to R&D. Leveraging a robust technical foundation and global infrastructure, Asymchem provides fundamental development and commercial manufacturing services in response to the growing complexity of modern drug development. With decades of innovation and execution, Asymchem has evolved from a small molecule CDMO into a diversified partner supporting a wide range of modalities, including TIDES, biologics, drug products, clinical research, synthetic biology, and technology transfer. Trusted by more than 1,000 clients worldwide, including top 20 pharmaceutical companies and leading biotechs, backed by a proven track record of USFDA and other agency inspections, Asymchem supports over 700 clinical-stage projects and more than 40 commercial production projects for clients around the globe. These projects are underpinned by our strong commitment to cGMP compliance and environmental health and safety (EHS). Asymchem helps accelerate drug development, reduce time to market, and deliver client-centric, cost-effective solutions tailored to the complex challenges of modern pharmaceutical innovation.

Founded 1999